TechFlex is dedicated to assisting startups in the Series A and Seed money stages to achieve their objectives through a structured and supportive framework. Our approach focuses on providing tailored solutions that address the unique challenges faced by early-stage companies.
TechFlex is the catalyst for success in the medical device industry, offering comprehensive support to growing companies. With expertise spanning from initial concept to market entry, TechFlex provides tailored solutions, cutting-edge technologies, and regulatory guidance.
Cerevasc announced recently that it has received its second Breakthrough Device designation from the US Food and Drug Administration (FDA) for its investigational eShunt system.This latest designation pertains to the treatment of communicating hydrocephalus in paediatric patients aged 12 years and…
Read the full article at: neuronewsinternational.com
